CN108404110A - One age in days hatching device spray delivery of poultry aquatic bird purifies medication - Google Patents
One age in days hatching device spray delivery of poultry aquatic bird purifies medication Download PDFInfo
- Publication number
- CN108404110A CN108404110A CN201810223192.0A CN201810223192A CN108404110A CN 108404110 A CN108404110 A CN 108404110A CN 201810223192 A CN201810223192 A CN 201810223192A CN 108404110 A CN108404110 A CN 108404110A
- Authority
- CN
- China
- Prior art keywords
- age
- chick
- purifies
- days
- medication
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000012447 hatching Effects 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 229940079593 drug Drugs 0.000 title claims abstract description 15
- 244000144977 poultry Species 0.000 title claims abstract description 10
- 239000007921 spray Substances 0.000 title claims abstract description 9
- 238000012384 transportation and delivery Methods 0.000 title claims abstract description 8
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 17
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960000740 enrofloxacin Drugs 0.000 claims abstract description 9
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims abstract description 8
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 claims abstract description 8
- 229960003080 taurine Drugs 0.000 claims abstract description 8
- 241000287828 Gallus gallus Species 0.000 claims abstract description 6
- UURAUHCOJAIIRQ-QGLSALSOSA-N tiamulin Chemical compound CCN(CC)CCSCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@@]23CC[C@@H](C)[C@]1(C)[C@@H]2C(=O)CC3 UURAUHCOJAIIRQ-QGLSALSOSA-N 0.000 claims abstract description 6
- 229960004885 tiamulin Drugs 0.000 claims abstract description 6
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 claims abstract description 5
- 230000037396 body weight Effects 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 3
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 6
- 241000589517 Pseudomonas aeruginosa Species 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000015181 infectious disease Diseases 0.000 abstract description 5
- 241000607142 Salmonella Species 0.000 abstract description 4
- 238000009395 breeding Methods 0.000 abstract description 4
- 230000001488 breeding effect Effects 0.000 abstract description 4
- 241000191967 Staphylococcus aureus Species 0.000 abstract description 3
- 238000000889 atomisation Methods 0.000 abstract description 3
- 230000035568 catharsis Effects 0.000 abstract description 3
- 238000001647 drug administration Methods 0.000 abstract description 3
- 235000021393 food security Nutrition 0.000 abstract description 3
- 210000004072 lung Anatomy 0.000 abstract description 3
- 235000016709 nutrition Nutrition 0.000 abstract description 3
- 210000002345 respiratory system Anatomy 0.000 abstract description 3
- 238000005507 spraying Methods 0.000 abstract description 3
- 230000005570 vertical transmission Effects 0.000 abstract description 3
- 241000204003 Mycoplasmatales Species 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 241000204031 Mycoplasma Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000588921 Enterobacteriaceae Species 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 241000588748 Klebsiella Species 0.000 description 2
- HACHPVCYFLSKSB-UMJDSZQGSA-N ManNAz-DBCO-Pam3CSK4 Chemical compound CCCCCCCCCCCCCCCC(N[C@H](CSCC(COC(CCCCCCCCCCCCCCC)=O)OC(CCCCCCCCCCCCCCC)=O)C(N[C@H](CO)C(N[C@H](CCCCN)C(N[C@H](CCCCN)C(N[C@H](CCCCN)C(N[C@H](CCCCN)C(NCCC(N(C1)C2=CC=CC=C2C2N(C(N[C@H]([C@H](C3)O)[C@H]([C@@H]([C@@H](CO)O)O)O[C@@]3(C(O)=O)O)=O)N=NC2C2=C1C=CC=C2)=O)=O)=O)=O)=O)=O)=O)=O HACHPVCYFLSKSB-UMJDSZQGSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 241000589886 Treponema Species 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000000022 bacteriostatic agent Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 230000009965 odorless effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- 241000606748 Actinobacillus pleuropneumoniae Species 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010004542 Bezoar Diseases 0.000 description 1
- 208000014085 Chronic respiratory disease Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 241001293418 Mannheimia haemolytica Species 0.000 description 1
- 201000008235 Mycoplasma pneumoniae pneumonia Diseases 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 241000222350 Pleurotus Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035724 Pneumonia mycoplasmal Diseases 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 206010047400 Vibrio infections Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- -1 diterpene alkenes Chemical class 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- AVRGPVXXZLTCBB-UHFFFAOYSA-N methane oxalonitrile Chemical compound N#CC#N.C AVRGPVXXZLTCBB-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940051027 pasteurella multocida Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 201000006509 pleuropneumonia Diseases 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a kind of one age in days hatching device spray deliveries of poultry aquatic bird to purify medication, is made of Tiamulin, neomycinsulphate, Enrofloxacin, muramyl dipeptide, taurine；The advantage of the invention is that：It is administered in hatching device internal spraying, completely after atomization, utilize lung's inhalation-type drug administration, the chicken of shell has just been gone out to an age in days or newly-hatched duckling purifies, combine Chinese breeding environment, breeder purifies present situation etc., and fully take into account the pharmacokinetics factor of drug, and the nutritional need of chick, the mycoplasma of vertical transmission is easy to chick, salmonella, the staphylococcus aureus of easy infection in hatching process, Pseudomonas aeruginosa, Escherichia coli etc. have comprehensive catharsis, in view of chick can lack energy in transportational process, situations such as damage that stress can cause respiratory tract villus of transport, the health-physical fitness of chick can be improved comprehensively, reduce disease, improve food security.
Description
Technical field
The present invention relates to a kind of hatching device purify medication, specifically a kind of one age in days hatching device of poultry aquatic bird spray to
Medicine purifies medication, belongs to hatching device purification medication field.
Background technology
In the highdensity breeding environment of China, the infection of mycoplasma is a big problem, can not only intractable be caused to be exhaled
Road problem is inhaled, and has tremendous influence to feed conversion rate.
It is generally purified now using an age in days injection of antibiotics class in the hatching Room, it is time-consuming to take manpower, antibiotic usage
Dosage is big, and operation has certain danger, and there are the huge hidden danger of cross-infection；Although injection of antibiotics, still
Without purifying the mycoplasma subclinical infection problem of chick respiratory mucosa well.
Invention content
To solve the above-mentioned problems, the present invention devises a kind of one age in days hatching device spray delivery of poultry aquatic bird purification use
Medicine is administered in hatching device internal spraying, and completely after atomization, using lung's inhalation-type drug administration, the chicken or newly-hatched duckling of shell have just been gone out to an age in days
It is purified, combines Chinese breeding environment, breeder purification present situation etc., and fully take into account the pharmacokinetics factor of drug,
And the nutritional need of chick, it is easy mycoplasma, the salmonella of vertical transmission to chick, easy infection is golden yellow in hatching process
Color staphylococcus, Pseudomonas aeruginosa, Escherichia coli etc. have comprehensive catharsis, it is contemplated that chick can lack in transportational process
Situations such as energy, the damage that stress can cause respiratory tract villus of transport, can improve the health-physical fitness of chick, reduce disease comprehensively
Occur, improves food security.
The technical scheme is that：
One age in days hatching device spray delivery of poultry aquatic bird purifies medication, consists of the following compositions：
5 milligrams of Tiamulin per kilogram of body weight, 5 milligrams of neomycinsulphate per kilogram of body weight, 5 milli of Enrofloxacin per kilogram of body weight
Gram, 1 milligram of muramyl dipeptide per kilogram of body weight, 10 milligrams of taurine per kilogram of body weight.
Wherein, per kilogram of body weight here refers to that an age in days has just gone out the chicken of shell or the weight of newly-hatched duckling.
Tiamulin（Tiamulin）It is to be fermented to be cut by higher fungus basidiomycetes Pleurotus Pleurotus mutilus
After short pleurin, then through chemical synthesis obtain hydrogenation fumarate, be a kind of special antibiotic of diterpene alkenes livestock and poultry.Its antibacterial
, main resisting gram-positive bacteria similar to macrolide antibiotics is composed, to staphylococcus aureus, streptococcus, mycoplasma, pig
Actinobacillus pleuropneumoniae, pig treponema dysentery etc. have stronger inhibiting effect, by force and macrolide to the effect of mycoplasma
Class.It is weaker to Gram-negative bacteria especially enterobacteriaceae effect.It is mainly used for preventing chronic respiratory disease, porcine mycoplasmal pneumonia
（Asthma）, actinomyces property pleuropneumonia and treponema dysentery etc..Low dosage can promote to grow, and improve feed conversion
Rate.
Neomycinsulphate is Tri-Biocin, is a kind of aminoglycoside antibiotics, which is the powder of white or off-white color
End, it is odorless, easily draw wet；To staphylococcus (methicillin-sensitivity strain), corynebacterium, escherichia coli, klebsiella
The enterobacteriaceae lactobacteriaceaes such as category, Proteus have good antibacterial action, to each group of streptococcus, streptococcus pneumonia, enterococcus spp etc.
Poor activity.
Enrofloxacin（Enrofloxacin）Also known as Ethyl Ciprofloxacin, Enrofloxacin.Belong to the change of Fluoroquinolones
Synthesis bacteriostatic agent is learned, is yellowish or light yellow crystalline powder, bitter is not soluble in water, is soluble in sodium hydroxide solution, methanol
And the organic solvents such as cyanogen methane.For broad-spectrum sterilization medicine, there is special efficacy to mycoplasma.To Escherichia coli, klebsiella bacillus, Salmonella
Bacterium, proteus, Pseudomonas aeruginosa, haemophilus, pasteurella multocida, pasteurella haemolytica, S. aureus L-forms, streptococcus etc. are all
There is sterilization effectiveness.Enrofloxacin can be used as animal-use drug product, long half time in animal body, there is good tissue distribution,
Belong to broad-spectrum bacteriostatic agent, there is bacteriostasis for gram-positive bacteria, negative bacterium and Mycoplasma, is employed in cultivation fish
The vibrios disease of class and the control of Escherichia coli disease.
Muramyl dipeptide (Muramyl Dipeptide, MDP) is that have immunolgical adjuvant activity in mycobacterial cells skeleton
Minimal structure unit, it can instead the whole mycobacteria in Freund's complete adjuvant (FCA), promote body exogenous antigen
Specific immune response.Muramyl dipeptide (Muramyl Dipeptide, MDP) is that have to exempt from mycobacterial cells skeleton
The minimal structure unit of epidemic disease adjuvanticity, it can instead the whole mycobacteria in Freund's complete adjuvant (FCA) promotes body pair
The specific immune response of exogenous antigen.(1) 1. immunoregulation effects of bioactivity and application:MDP can promote in mineral oil
Immune response into different genera animal to antigen, oral aqueous solution can promote antibody tormation to increase, enhancing natural vaccine and
Tetanus toxoid, Pseudomonas aeruginosa toxoid, hepatitis B surface antibody (HBSAg) and plasmodium falciparum and artificial antigen are such as
The immune effect of HBSAg ~ (16) peptide fragment etc..
Taurine（Taurine）Also known as beta-amino ethanesulfonic acid earliest by being separated in cow-bezoar, therefore is gained the name.Sterling is nothing
Color or the ramp-like crystal of white, odorless, taurine chemical property is stablized, and is a kind of sulfur-bearing insoluble in organic solvents such as ether
Non-protein amino acid exists with free state in vivo, is not involved in the biosynthesis of vivo protein.Although taurine is not involved in
Protein synthesizes, but it is closely related with the metabolism of cystine, cysteine.
The advantage of the invention is that：It is administered in hatching device internal spraying, it is right using lung's inhalation-type drug administration completely after atomization
One age in days has just gone out the chicken of shell or newly-hatched duckling is purified, and combines Chinese breeding environment, breeder purification present situation etc., and fully take into account
The pharmacokinetics factor of drug and the nutritional need of chick are easy chick mycoplasma, the salmonella of vertical transmission,
The staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli etc. of easy infection have comprehensive catharsis in hatching process, it is contemplated that
Situations such as chick can lack energy in transportational process, the damage that stress can cause respiratory tract villus of transport, can improve comprehensively
The health-physical fitness of chick reduces disease, improves food security.
The present invention is further explained in the light of specific embodiments.
Specific implementation mode
Hereinafter, preferred embodiments of the present invention will be described, it should be understood that preferred embodiment described herein is only used
In the description and interpretation present invention, it is not intended to limit the present invention.
The percentage sign " % " arrived involved in the present invention refers to mass percent if not specified；But the percentage of solution,
Unless otherwise specified, refer to containing several grams of solute in solution 100ml；Percentage between liquid, capacity when referring to 20 DEG C
Ratio.
Embodiment 1
A kind of one age in days hatching device spray delivery of poultry aquatic bird purification medication, consists of the following compositions：
5 milligrams of Tiamulin per kilogram of body weight, 5 milligrams of neomycinsulphate per kilogram of body weight, 5 milli of Enrofloxacin per kilogram of body weight
Gram, 1 milligram of muramyl dipeptide per kilogram of body weight, 10 milligrams of taurine per kilogram of body weight.
Wherein, per kilogram of body weight here refers to that an age in days has just gone out the chicken of shell or the weight of newly-hatched duckling.
Claims (2)
1. one age in days hatching device spray delivery of poultry aquatic bird purifies medication, which is characterized in that consist of the following compositions：
5 milligrams of Tiamulin per kilogram of body weight, 5 milligrams of neomycinsulphate per kilogram of body weight, 5 milli of Enrofloxacin per kilogram of body weight
Gram, 1 milligram of muramyl dipeptide per kilogram of body weight, 10 milligrams of taurine per kilogram of body weight.
2. one age in days hatching device spray delivery of poultry aquatic bird according to claim 1 purifies medication, it is characterised in that：It is described
Per kilogram of body weight refer to that an age in days has just gone out the chicken of shell or the weight of newly-hatched duckling.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810223192.0A CN108404110A (en) | 2018-03-19 | 2018-03-19 | One age in days hatching device spray delivery of poultry aquatic bird purifies medication |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810223192.0A CN108404110A (en) | 2018-03-19 | 2018-03-19 | One age in days hatching device spray delivery of poultry aquatic bird purifies medication |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108404110A true CN108404110A (en) | 2018-08-17 |
Family
ID=63132064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810223192.0A Pending CN108404110A (en) | 2018-03-19 | 2018-03-19 | One age in days hatching device spray delivery of poultry aquatic bird purifies medication |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108404110A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111387135A (en) * | 2020-03-13 | 2020-07-10 | 北京家禽育种有限公司 | Method for systematically monitoring and purifying pseudomonas aeruginosa in hatching process |
-
2018
- 2018-03-19 CN CN201810223192.0A patent/CN108404110A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| （苏）B.Д.索科洛夫: "《家禽抗微生物药》", 30 November 1988, 农业出版社 * |
| 李荣誉等: "家禽常用抗生素的联合用药", 《中国家禽》 * |
| 陶增思: "鸡体平衡防御网构建与疾病防治理念的建立", 《北方牧业》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111387135A (en) * | 2020-03-13 | 2020-07-10 | 北京家禽育种有限公司 | Method for systematically monitoring and purifying pseudomonas aeruginosa in hatching process |
| CN111387135B (en) * | 2020-03-13 | 2021-10-29 | 北京家禽育种有限公司 | Method for systematically monitoring and purifying pseudomonas aeruginosa in hatching process |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2673233C2 (en) | Clay product and uses thereof | |
| AU2009313998B2 (en) | Chitosan derivatives to treat animals or optimize animal health | |
| AU2689699A (en) | Small molecules that increase the conversion of food to body weight gain | |
| JPH0720876B2 (en) | Microbiota colonization method | |
| CN109512999B (en) | Use of aliphatic alcohols containing oxygenated hydrocarbon derivatives as a synergist for polymyxins | |
| CN108404110A (en) | One age in days hatching device spray delivery of poultry aquatic bird purifies medication | |
| US20110144048A1 (en) | Novel Uses of Neuraminidase Inhibitors in Infectious Diseasess | |
| JP2572562B2 (en) | Bacteria producing antibiotics LL-E19020α and β | |
| CN102793713A (en) | Lincomycin hydrochloride-spectinomycin sulfate injection and preparation method thereof | |
| WO2016207744A1 (en) | Improved process for production and purification of capsular pneumococcal polysaccharide from streptococcus pneumoniae and method for producing conjugate vaccine composition using said polysaccharide | |
| US3629451A (en) | Method of treating bacterial infections | |
| CN117679362B (en) | Veterinary valnemulin solution and preparation method and application thereof | |
| Goren et al. | Therapeutic efficacy of medicating drinking water with spectinomycin and lincomycinspectinomycin in experimental Escherichia coli infection in poultry | |
| ES2369138T3 (en) | COMPOSITIONS FOR VETERINARY AND MEDICAL APPLICATIONS. | |
| CN109602902B (en) | Swine pasteurella polysaccharide protein coupling vaccine and preparation method thereof | |
| RU2800827C1 (en) | Method of escherichiosis treatment in calves | |
| CN103356663A (en) | Sulfamonomethoxine-ciprofloxacin-fosfomycin combined injection for veterinary use and preparation method thereof | |
| US4147802A (en) | Method of treating bacterial infections | |
| Al-Kheraije | Studies on the antibacterial activity of ceftiofur sodium in vitro and birds | |
| RU2356543C1 (en) | Preparation "gental" for treatment of gastrointestinal, respiratory diseases in calves and piglets of bacterial etiology and method of treating gastrointestinal, respiratory diseases in calves and piglets of bacterial etiology | |
| US20190046467A1 (en) | Compositions and methods for inhibiting biofilm-forming bacteria | |
| RU2246309C1 (en) | Method for prophylaxis of chlamydium bronchopneumonia in calves | |
| CN105456281A (en) | Medicine composition for livestock and preparation method and application thereof | |
| JPS60133000A (en) | Glycopeptide biologically converted product | |
| US9655962B2 (en) | Methods and compositions for reducing microorganisms in the oropharynx, nasopharynx and oral cavities |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180817 |
|
| RJ01 | Rejection of invention patent application after publication |